<rst>
<header>
	<relations>
			<rel name="Analogy" type="multinuc"/>
			<rel name="Cause-Result" type="multinuc"/>
			<rel name="Comment-Topic" type="multinuc"/>
			<rel name="Comparison" type="multinuc"/>
			<rel name="Conclusion" type="multinuc"/>
			<rel name="Consequence" type="multinuc"/>
			<rel name="Contrast" type="multinuc"/>
			<rel name="Disjunction" type="multinuc"/>
			<rel name="Evaluation" type="multinuc"/>
			<rel name="Interpretation" type="multinuc"/>
			<rel name="Inverted-Sequence" type="multinuc"/>
			<rel name="List" type="multinuc"/>
			<rel name="Otherwise" type="multinuc"/>
			<rel name="Problem-Solution" type="multinuc"/>
			<rel name="Proportion" type="multinuc"/>
			<rel name="Question-Answer" type="multinuc"/>
			<rel name="Reason" type="multinuc"/>
			<rel name="Same-Unit" type="multinuc"/>
			<rel name="Sequence" type="multinuc"/>
			<rel name="Statement-Response" type="multinuc"/>
			<rel name="Temporal-Same-Time" type="multinuc"/>
			<rel name="TextualOrganization" type="multinuc"/>
			<rel name="Topic-Comment" type="multinuc"/>
			<rel name="Topic-Drift" type="multinuc"/>
			<rel name="Topic-Shift" type="multinuc"/>
			<rel name="analogy-e" type="rst"/>
			<rel name="analogy" type="rst"/>
			<rel name="antithesis-e" type="rst"/>
			<rel name="antithesis" type="rst"/>
			<rel name="attribution-e" type="rst"/>
			<rel name="attribution-n-e" type="rst"/>
			<rel name="attribution-n" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="background-e" type="rst"/>
			<rel name="background" type="rst"/>
			<rel name="cause-e" type="rst"/>
			<rel name="cause" type="rst"/>
			<rel name="circumstance-e" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="comment-e" type="rst"/>
			<rel name="comment" type="rst"/>
			<rel name="comparison-e" type="rst"/>
			<rel name="comparison" type="rst"/>
			<rel name="concession-e" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="conclusion-e" type="rst"/>
			<rel name="conclusion" type="rst"/>
			<rel name="condition-e" type="rst"/>
			<rel name="condition" type="rst"/>
			<rel name="consequence-n-e" type="rst"/>
			<rel name="consequence-n" type="rst"/>
			<rel name="consequence-s-e" type="rst"/>
			<rel name="consequence-s" type="rst"/>
			<rel name="contingency-e" type="rst"/>
			<rel name="contingency" type="rst"/>
			<rel name="definition-e" type="rst"/>
			<rel name="definition" type="rst"/>
			<rel name="elaboration-additional-e" type="rst"/>
			<rel name="elaboration-additional" type="rst"/>
			<rel name="elaboration-general-specific-e" type="rst"/>
			<rel name="elaboration-general-specific" type="rst"/>
			<rel name="elaboration-object-attribute-e" type="rst"/>
			<rel name="elaboration-object-attribute" type="rst"/>
			<rel name="elaboration-part-whole-e" type="rst"/>
			<rel name="elaboration-part-whole" type="rst"/>
			<rel name="elaboration-process-step-e" type="rst"/>
			<rel name="elaboration-process-step" type="rst"/>
			<rel name="elaboration-set-member-e" type="rst"/>
			<rel name="elaboration-set-member" type="rst"/>
			<rel name="enablement-e" type="rst"/>
			<rel name="enablement" type="rst"/>
			<rel name="evaluation-n-e" type="rst"/>
			<rel name="evaluation-n" type="rst"/>
			<rel name="evaluation-s-e" type="rst"/>
			<rel name="evaluation-s" type="rst"/>
			<rel name="evidence-e" type="rst"/>
			<rel name="evidence" type="rst"/>
			<rel name="example-e" type="rst"/>
			<rel name="example" type="rst"/>
			<rel name="explanation-argumentative-e" type="rst"/>
			<rel name="explanation-argumentative" type="rst"/>
			<rel name="hypothetical-e" type="rst"/>
			<rel name="hypothetical" type="rst"/>
			<rel name="interpretation-n-e" type="rst"/>
			<rel name="interpretation-n" type="rst"/>
			<rel name="interpretation-s-e" type="rst"/>
			<rel name="interpretation-s" type="rst"/>
			<rel name="manner-e" type="rst"/>
			<rel name="manner" type="rst"/>
			<rel name="means-e" type="rst"/>
			<rel name="means" type="rst"/>
			<rel name="otherwise-e" type="rst"/>
			<rel name="otherwise" type="rst"/>
			<rel name="preference-e" type="rst"/>
			<rel name="preference" type="rst"/>
			<rel name="problem-solution-n-e" type="rst"/>
			<rel name="problem-solution-n" type="rst"/>
			<rel name="problem-solution-s-e" type="rst"/>
			<rel name="problem-solution-s" type="rst"/>
			<rel name="purpose-e" type="rst"/>
			<rel name="purpose" type="rst"/>
			<rel name="question-answer-n-e" type="rst"/>
			<rel name="question-answer-n" type="rst"/>
			<rel name="question-answer-s-e" type="rst"/>
			<rel name="question-answer-s" type="rst"/>
			<rel name="reason-e" type="rst"/>
			<rel name="reason" type="rst"/>
			<rel name="restatement-e" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="result-e" type="rst"/>
			<rel name="result" type="rst"/>
			<rel name="rhetorical-question-e" type="rst"/>
			<rel name="rhetorical-question" type="rst"/>
			<rel name="statement-response-n-e" type="rst"/>
			<rel name="statement-response-n" type="rst"/>
			<rel name="statement-response-s-e" type="rst"/>
			<rel name="statement-response-s" type="rst"/>
			<rel name="summary-n-e" type="rst"/>
			<rel name="summary-n" type="rst"/>
			<rel name="summary-s-e" type="rst"/>
			<rel name="summary-s" type="rst"/>
			<rel name="temporal-after-e" type="rst"/>
			<rel name="temporal-after" type="rst"/>
			<rel name="temporal-before-e" type="rst"/>
			<rel name="temporal-before" type="rst"/>
			<rel name="temporal-same-time-e" type="rst"/>
			<rel name="temporal-same-time" type="rst"/>
			<rel name="topic-drift-e" type="rst"/>
			<rel name="topic-drift" type="rst"/>
			<rel name="topic-shift-e" type="rst"/>
			<rel name="topic-shift" type="rst"/>
		</relations>
</header>
<body>
		<segment id="1" parent="32" relname="TextualOrganization">DISCUSSION</segment>
		<segment id="2" parent="5" relname="analogy-e">In this 15-centre , 6-week , parallel group , randomized controlled trial</segment>
		<segment id="3" >conducted in Indian outpatients with major depressive disorder</segment>
		<segment id="4" >that was at least moderate in severity ,</segment>
		<segment id="5" parent="42" relname="span">PB was as effective as sertraline in attenuating depression rating scores on the HAM-D and MADRS.</segment>
		<segment id="6" parent="40" relname="summary-s">Statistically significant improvement in HAM-D and MADRS scores were evident at the end of 2 weeks of treatment , itself.</segment>
		<segment id="7" parent="35" relname="span">The response</segment>
		<segment id="8" parent="7" relname="elaboration-additional-e">(90 %)</segment>
		<segment id="9" parent="36" relname="span">and remission</segment>
		<segment id="10" parent="9" relname="elaboration-additional-e">(70 %)</segment>
		<segment id="11" parent="37" relname="span">rates with PB were high ,</segment>
		<segment id="12" >and were comparable with those achieved with sertraline</segment>
		<segment id="13" parent="11" relname="elaboration-additional-e">(92 % and 75 % , respectively).</segment>
		<segment id="14" parent="38" relname="Contrast">PB was very well tolerated</segment>
		<segment id="15" >and was associated with significantly less nausea and headache than sertraline ;</segment>
		<segment id="16" parent="39" relname="span">in contrast , no adverse event occurred at a greater frequency with PB relative to sertraline.</segment>
		<segment id="17" parent="16" relname="explanation-argumentative">PB did not adversely affect heart rate , blood pressure , hematological measures , biochemical measures , metabolic measures , and the EKG.</segment>
		<segment id="18" parent="43" relname="span">These data confirm in Indian patients the favorable results</segment>
		<segment id="19" >obtained for PB in the Phase III regulatory trials</segment>
		<segment id="20" >conducted in the North American and European continents.</segment>
		<segment id="21" parent="18" relname="attribution">[8 -- 11]</segment>
		<segment id="22" parent="44" relname="span">The recommended dosing range of PB is 75-300 mg/day ,</segment>
		<segment id="23" parent="22" relname="elaboration-object-attribute-e">as identified in the Phase III clinical trials.</segment>
		<segment id="24" parent="44" relname="attribution">[8 -- 11]</segment>
		<segment id="25" parent="50" relname="span">It is noteworthy that ,</segment>
		<segment id="26" parent="25" relname="circumstance-e">in this Indian study ,</segment>
		<segment id="27" parent="51" relname="span">the mean endpoint dose was 250 mg/day ;</segment>
		<segment id="28" parent="27" relname="elaboration-additional-e">that is , towards the higher end of the dosing range.</segment>
		<segment id="29" parent="30" relname="condition">Despite the administration of these higher doses ,</segment>
		<segment id="30" parent="52" relname="span">PB was tolerated as well as or better than sertraline.</segment>
		<segment id="31" parent="55" relname="conclusion">PB therefore appears to be a useful addition to the therapeutic armamentarium for the treatment of major depressive disorder in Indian patients.</segment>
		<group id="32" type="multinuc" />
		<group id="33" type="span" parent="54" relname="Topic-Drift"/>
		<group id="34" type="multinuc" parent="40" relname="span"/>
		<group id="35" type="span" parent="34" relname="Same-Unit"/>
		<group id="36" type="span" parent="34" relname="Same-Unit"/>
		<group id="37" type="span" parent="34" relname="Same-Unit"/>
		<group id="38" type="multinuc" parent="46" relname="Topic-Drift"/>
		<group id="39" type="span" parent="38" relname="Contrast"/>
		<group id="40" type="span" parent="41" relname="span"/>
		<group id="41" type="span" parent="46" relname="Topic-Drift"/>
		<group id="42" type="span" parent="33" relname="span"/>
		<group id="43" type="span" parent="47" relname="conclusion"/>
		<group id="44" type="span" parent="45" relname="span"/>
		<group id="45" type="span" parent="54" relname="Topic-Drift"/>
		<group id="46" type="multinuc" parent="47" relname="span"/>
		<group id="47" type="span" parent="48" relname="span"/>
		<group id="48" type="span" parent="42" relname="elaboration-additional"/>
		<group id="49" type="multinuc" parent="54" relname="Topic-Drift"/>
		<group id="50" type="span" parent="49" relname="Same-Unit"/>
		<group id="51" type="span" parent="49" relname="Same-Unit"/>
		<group id="52" type="span" parent="53" relname="Analogy"/>
		<group id="53" type="multinuc" parent="54" relname="Topic-Drift"/>
		<group id="54" type="multinuc" parent="55" relname="span"/>
		<group id="55" type="span" parent="56" relname="span"/>
		<group id="56" type="span" parent="32" relname="TextualOrganization"/>
  </body>
</rst>